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There is a consensus that age-related macular degeneration (AMD) is the result ofQ1 (photo)-
oxidative-induced retinal injury and its inflammatory sequelae, the latter being influenced by
genetic background. The dietary carotenoids, lutein (L), zeaxanthin (Z), and meso-zeaxanthin
(meso-Z), accumulate at the macula, where they are collectively known as macular pigment
(MP). The anatomic (central retinal), biochemical (anti-oxidant) and optical (short-wave-
length-filtering) properties of this pigment have generated interest in the biologically plau-
sible rationale that MP may confer protection against AMD. Level 1 evidence has shown that
dietary supplementation with broad-spectrum anti-oxidants results in risk reduction for AMD
progression. Studies have demonstrated that MP rises in response to supplementation with
the macular carotenoids, although level 1 evidence that such supplementation results in risk
reduction of AMD and/or its progression is still lacking. Although appropriately weighted
attention should be accorded to higher levels of evidence, the totality of available data should
be appraised in an attempt to inform professional practice. In this context, the literature
demonstrates that supplementation with the macular carotenoids is probably the best means
of fortifying the anti-oxidant defenses of the macula, thus putatively reducing the risk of AMD
and/or its progression.
Keywords:
Age-related macular degeneration / Lutein / Macular pigment / Meso-zeaxanthin /
Zeaxanthin
1 Introduction
The macula is a specialisedQ2 area of the retina, responsible for
high acuity central vision and the perception of colour [1].
Age-related macular degeneration (AMD) is a degenerative
condition of the macula, and its late form (i.e. visually
consequential AMD, or VC AMD) is the leading cause of
blindness in the developed world [2–5]. The prevalence of
AMD will rise due to increasing life expectancy and the
demographic shift towards an elderly population [6, 7]. VC
AMD has a significant adverse impact on daily living,
independence, emotional well being and overall quality of
life, which are related to disease severity [8–10], not to
mention the substantial personal and societal burden that
this condition represents [11, 12].
The aetiology of AMD is poorly understood, yet there is
consensus that genetic background and certain environ-
mental/lifestyle risk factors, and their interaction, predis-
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pose an individual to the condition [13, 14]. Current treat-
ment interventions, such as anti-vascular endothelial growth
factor (anti-VEGF) agents, have resulted in better outcomes
for patients with neovascular AMD [15–17]. Yet these are
costly and cumbersome to the healthcare provider and to the
patient. In addition, there is no effective treatment for
atrophic AMD, which has a similarly detrimental effect on a
patient’s quality of life.
Two dietary carotenoids, lutein (L) and zeaxanthin (Z),
and a typically non-dietary carotenoid, meso-zeaxanthin
(meso-Z), accumulate at the macula where they are collec-
tively known as macular pigment (MP) and give the
macula its yellow appearance. L and Z can be obtained from
many foods [18], whereas meso-Z is not present in a
conventional western diet, although it can be found in
certain types of seafood [19]. A biochemical study on
monkey retinas found that meso-Z is generated from L
in the primate retina [20]. Z (including meso-Z) is the
predominant carotenoid in the foveal (central) region,
whereas L predominates in the parafoveal (paracentral)
region. Interestingly, meso-Z is found only in the epicentre
of the macula [21].
MP has generated interest in the recent years because of
its possible protective role in AMD, putatively attributable to
its anti-oxidant properties and/or its pre-receptoral filtration
of damaging (short-wavelength) blue light [22, 23]. There is
a clear need for attention to be directed towards the
prevention of AMD and its progression.
2 AMD aetiopathogenesis
2.1 Oxidative stress
As AMD is an age-related condition, the free radical theory
of ageing is believed to be relevant to its aetiopathogenesis.
This theory proposes that age-related disorders are the result
of cumulative tissue damage following interaction with
reactive oxygen intermediates (ROIs) [24, 25]. ROIs, which
include free radicals, hydrogen peroxide and singlet oxygen,
are unstable byproducts of oxygen metabolism. Free radi-
cals, for example, lack (or possess an additional) electron in
their outer orbit, and therefore seek to be neutralized by
obtaining or transferring, respectively, an electron; a readily
available source of electrons includes the double bond of a
polyunsaturated fatty acid (PUFA). Thus, ROIs readily react
with tissue macromolecules, resulting in impaired cell
function and cell death [26]. The body’s natural defence
against ROIs includes their neutralisation by enzymes and/
or anti-oxidants [27]. However, generation of ROIs increases
in response to environmental stresses, such as atmospheric
pollution, asbestos exposure, tobacco use, irradiation and
alcohol consumption [28, 29]. Oxidative injury occurs,
therefore, when the level of oxidants (ROIs) in a system
exceeds the detoxifying capacity of its anti-oxidant defence
system [30].
The retina is made up of two layers, the photoreceptor-
and axon-containing neurosensory retina, and the under-
lying single-layer retinal pigment epithelium (RPE). The
function of the RPE is to nurture, and remove waste
products from, the neurosensory retina [31, 32]. AMD is
characterised by loss of photoreceptors and by RPE cell
dysfunction [33], the latter being largely attributable to an
age-related accumulation of lipofuscin (yellow-brown
pigment granules representing lipid-containing residues of
lysosomal digestion) [34]. Of note, the accumulation of
lipofuscin within the RPE cells increases as a result of
incomplete digestion of oxidatively damaged photoreceptor
outer segment membranes [35]. In turn, this yellow age
pigment then acts as a photosensitiser (a compound which,
when irradiated with light of an appropriate wavelength,
emits an electron, thereby generating an ROI) [23, 36], thus
provoking further oxidative injury [35, 37].
The retina is an ideal tissue for the production of ROIs,
because of its high oxygen demand and consumption,
exposure to visible light, metabolic activities (such as RPE
phagocytosis) and the presence of photosensitisers (chro-
mophores) [38]. In addition, the photoreceptor outer
segments contain a high concentration of PUFAs, which are
readily oxidised by ROIs, thus generating a cytotoxic chain
reaction of events, thereby producing yet more ROIs and
further and consequential oxidative injury [23, 28].
Light of shorter wavelengths (blue, ultraviolet (UV)) has
greater energy than that of longer wavelengths (e.g. red,
yellow) and is, therefore, more injurious to retinal tissue
[39]. In the human eye, the cornea and crystalline lens
efficiently filter most of the ultraviolet light [40]. However,
substantial amounts of damaging, high energy, short-
wavelength, blue (visible) light is incident upon the retina,
even in an ambient setting [41].
Damage to the RPE and to the photoreceptors by visible
light was first demonstrated in 1965 [42]. Later, it was shown
that the blue part of the visible spectrum is most injurious
[43]. Of note, it has also been demonstrated that such blue
light (photo)-oxidative retinal damage is greater in the
presence of high oxygen tension [44]. Lipofuscin also
appears to play a decisive role in photo-oxidative stress in the
retina, inducing the production of ROIs when irradiated
with blue light as this pigment acts as a chromophore [45].
Indeed, and consistent with this, it has been shown that
lipofuscin in RPE cells stimulates cell apoptosis when
exposed to visible light [46, 47].
There is a growing consensus that cumulative lifetime
exposure to visible light increases the risk of AMD [22, 48],
consistent with the aforementioned findings. Furthermore,
AMD-like lesions have been demonstrated in laboratory rats
reared in ambient levels of light, when compared with rats
reared in the dark [49]. Subsequent investigators have
demonstrated that the generation of AMD-like lesions in
monkey retinas, following exposure to light of varying
wavelengths, requires 70–1000 times less power when using
blue light compared with infrared wavelengths [50]. And
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finally, administration of anti-oxidants to laboratory rats
exposed to continuous illumination has been shown to
confer protection against photoreceptor loss [51]. In other
words, there is a compelling body of evidence that cumu-
lative exposure to visible (blue) light is an important
contributor to the development of AMD and that the
mechanism of its contribution rests on the (photo)-oxidative
injury that such short wavelengths of visible light inflict
upon the retina.
Of interest, ROI production (and, therefore, oxidative
injury) peaks at the macula [52, 53], where AMD manifests.
2.2 Inflammation
There is a consensus that inflammation also plays a role in
the pathogenesis of AMD [54, 55]. Inflammation is part of
the complex, biological, non-specific, immune response of
vascular tissue to harmful stimuli, such as pathogens,
damaged cells or irritants [56]. It is believed that inflam-
mation within the retina is a precursor to the formation of
drusen (yellow waste deposits in Bruch’s membrane under
the retina) and the alteration of the extracellular matrix
[57, 58]. These changes alter the RPE-choriocappillaris
relationship, ultimately causing choroidal neovascularisa-
tion and other manifestations of advanced AMD [55, 59]. Of
note, drusen have been shown to contain proteins associated
with immune-mediated response and inflammation [59, 60].
Indeed, histological studies have consistently demonstrated
the presence of chronic inflammatory cells in retinas
afflicted with AMD [61, 62]. It is believed that these
inflammatory cells damage tissue by releasing proteolytic
enzymes and oxidants, thus compounding oxidative stress.
The inflammatory hypothesis of AMD has generated a lot
of interest, especially given the discovery that subjects with a
certain gene variant, one which is closely connected to the
mediation of inflammatory processes, are significantly more
at risk of developing AMD [63, 64].
Hollyfield et al. have eloquently shown that oxidative
damage-induced inflammation is the initiator of AMD. The
investigators demonstrated AMD-like lesions in mice
immunized with mouse-serum albumin adducted with
carboxyethylpyrrole, a unique oxidation product of docosa-
hexaenoic acid known to adduct proteins in drusen from
AMD donor eyes. Thusly immunized mice develop anti-
bodies to this hapten, fix complement component-3 in
Bruch’s membrane (the site of drusen formation), accu-
mulate drusen below the RPE during ageing, and develop
atrophic changes within the RPE. In other words, it appears
that oxidative damage represents the trigger for the devel-
opment of AMD, the pathogenesis of which is mediated by
the inflammatory response to that insult which in turn will
be determined by genetic background. It follows, therefore,
that prevention or attenuation of the initial oxidative injury
will reduce the risk of developing AMD, regardless of
genetic background [65].
3 AMD risk factors
The three undisputed risk factors for AMD are: increasing
age, positive family history of the disease and tobacco use
[66–70]. Of note, the genetic predisposition to AMD is
subject to environmental provocation [13, 14, 71]. However,
there is a growing body of evidence that cumulative expo-
sure to visible light in association with a lack of dietary
intake of key anti-oxidants also represents an increased risk
of AMD [72]. Interestingly, the three established risk factors
for AMD (age, genetic background and tobacco use) are
associated with a relative lack of MP before disease onset
[73]. Moreover, a recent study has identified that age and
tobacco use are also associated with an atypical, and most
likely undesirable, central dip in the spatial profile of
MP [74].
4 MP
4.1 The origins of MP
The macula lutea (yellow spot) was first identified more than
two centuries ago. In 1792, Buzzi first described it in the
human eye [75], and later in 1795 Soemmering inde-
pendently discovered the foramine centrali limbo luteo
(the central yellow-edged hole) [76]. The first review on
‘‘macular yellow’’ was published by Home in 1798 [77],
which began an era of investigation into the composition,
and function, of what has become known as MP [78], a term
first coined in 1933 by Walls et al. [79]. The hypothesis that
this pigment provides protection against the damaging
effects of short-wavelength visible light was first proposed by
Max Shultze in 1866 [80], and its function was further
discussed in a series of studies in the early 20th century
[79, 81–83].
In 1945, Wald demonstrated the spectral sensitivity of
MP (using a spectral adaptometer), indicating that it had a
characteristic carotenoid absorption spectrum and belonged
to a family of xanthophylls found in green leaves [84].
However, it was not until as recent as 1985 that Bone and
Landrum first proposed that the pigment was composed of
the carotenoids, L and Z [85], and this was later confirmed
in 1988 by Handleman et al. [86]. Meso-Z was later identi-
fied as being the third carotenoid present in the central
retina, where it is the dominant carotenoid at the epicentre
of the macula [87]. Bone et al proposed that meso-Z was
primarily formed at the macula following conversion from
retinal L [21], and this has subsequently been confirmed
[20, 88, 89].
5 The functions of MP
The putative protective role of MP for AMD rests on at least
one of the two following properties of this pigment. First, its
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absorbance spectrum (peak absorption of this pigment is
460 nm). Second, the ability of the macular carotenoids to
quench ROIs, referred to as anti-oxidant capacity.
5.1 Short-wavelength light filtration
Although almost all UV-B (320–290 nm) and UV-A
(320–400 nm) light is absorbed by the cornea and lens, light
of slightly longer wavelength (400–520 nm) passes through
the anterior media, and irradiates the macula [90]. Given
that the peak absorption of MP is at 460 nm [84], it has the
ideal light filtration properties to screen short-wavelength
light pre-receptorally. This allows MP to attenuate the
amount of blue light incident upon the central retina.
L is reported to be a superior filter of blue light when
compared with Z, due to its orientation with respect to the
plane of the phospholipid bilayer of the cell membrane [91],
which is both parallel and perpendicular. In contrast, Z and
meso-Z only exhibit perpendicular orientation to this layer.
However, it is important to note that the different absorp-
tion spectra of these pigments (L, Z and meso-Z) result in a
collective optimal filtration of blue light at the macula,
which would not be achieved by any of these carotenoids in
isolation [91–93].
A recent analysis by the European Eye Study (n5 4753)
found a significant correlation between cumulative exposure
to visible light and neovascular AMD in those patients with
low intake of dietary anti-oxidants, including L and Z [94]. A
further study has recently reported the effect of low-power
laser light (476 nm (blue)) on the retinae of 8 rhesus
monkeys who had lifelong deprivation of the dietary
xanthophylls, and therefore no detectable MP. A further four
monkeys (controls) had a typical dietary intake of L and Z
from birth. The retinae of primates deprived of dietary
xanthophylls until exposed to the low-power laser light, but
then supplemented with either L or Z, were then exposed
once again to the same laser light six months later. The
relationship between lesion size and exposure energy was
then analysed. The controls (primates with typical dietary
intake of L and Z from birth) exhibited less severe blue-light
induced lesions in the foveal region of the retina when
compared to the parafoveal region (where there is no MP),
whereas those with lifetime deprivation of xanthophylls and
no measurable MP exhibited no difference between the
fovea and parafovea in terms of blue light-induced retinal
damage prior to supplementation, thus supporting the
hypothesis that foveal photoprotection is indeed attributable
to MP. This was further confirmed when, following either L
or Z supplementation, relative foveal protection was
restored, and these animals with prior lifelong deprivation
of dietary xanthophylls no longer exhibited greater relative
vulnerability of the fovea when compared with the parafo-
vea, and were therefore similar to the control group in this
respect following supplementation. In other words, and in
spite of long-term carotenoid deprivation, supplemental
macular carotenoids, whether L or Z, afforded the fovea
protection from blue light injury [95].
5.2 Anti-oxidant properties
L, Z and meso-Z are structural isomers of one another and
are characterized, biochemically, by their high number of
double bonds [21]. Their supply of readily available electrons
enables these carotenoids to quench ROIs, thus limiting
membrane phosopholipid peroxidation and attenuating
oxidative injury [91, 96, 97]. Kirschfeld was the first to
propose the idea that carotenoids protect the macula against
oxidative stress [98]. However, it was not until 1997 that
Khachik et al. confirmed the presence of direct oxidation
products of L and Z in human retinal tissue, supporting the
hypothesis that MP does indeed protect against oxidative
damage in this tissue [99].
The anti-oxidant capacity of Z (and other carotenoids),
however, has been shown to decrease with increasing
oxygen tensions in the tissue [100]. Of note, MP is at its
highest concentration in the receptor axon layer of the
foveola and in the inner plexiform layer [101, 102]. Also, the
concentration of the carotenoids within each retinal layer
peaks at the foveola. Importantly, it is at this central retinal
location where ROI production is greatest [103].
In vitro studies of human RPE cells, subjected to oxida-
tive stress, have shown enhanced survival of these cells in
the presence of Z and other anti-oxidants, when compared
with controls [104]. Furthermore, L and Z are also more
resistant to degradation than other carotenoids when
subjected to oxidative stress [105]. Z appears to be a more
potent anti-oxidant than L [106] and meso-Z is yet more
efficacious, but only in conjunction with its binding protein
[107]. Another study has demonstrated that light-induced
photoreceptor apoptosis is limited in response to supple-
mental Z in quail (the retinae of which, like those of
primates, selectively accumulate L and Z) [108]. Chucair
et al. provided the first evidence of direct neuroprotection of
photoreceptors by the macular carotenoids [109], by
demonstrating that the retinal neurons of rats in culture
were protected from oxidative stress when pre-treated with L
and Z, compared with those not pre-treated with these
carotenoids. Recently, Li et al. demonstrated that a mixture
of L, Z and meso-Z (in a ratio of 1:1:1) quenches more singlet
oxygen than any of these carotenoids individually but at the
same total concentration [110].
6 The source of the macular carotenoids
An average western diet contains 1.3–3mg/day of L and Z
combined [111], with significantly more L than Z (repre-
sented by an estimated ratio of circa 7:1). It has been
reported that approximately 78% of dietary L and Z is
sourced from vegetables, with L found in highest concen-
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trations in dark green leafy vegetables (including spinach,
broccoli, kale and collard greens) [18]. However, as most
current dietary databases report intakes of L and Z
combined, it has been difficult to assess the respective and
relative intakes of the individual macular carotenoids.
Recently, however, a study by Perry et al. did report
concentrations of L and Z separately within the major food
sources, as determined by the National Health and Nutrition
Examination Survey (NHANES). In their study, they
confirmed that green leafy vegetables were the richest
source of L (e.g. cooked spinach and kale), whereas corn and
corn products were confirmed as being a major source of Z
[112]. Eggs are also a good source of L and Z, especially
given the enhanced bioavailability of these carotenoids in
this form because of co-ingestion of fat [113].
It appears that humans ingest relatively low concentra-
tions of meso-Z (if any); however, research is ongoing in this
area, given the recent interest in this centrally located
macular carotenoid. To date, there has been no exhaustive
assessment of the amounts of meso-Z in a normal diet.
However, eggs from hens fed meso-Z are known to be a rich
human dietary source of this carotenoid [114]. Also, a study
by Maoka et al. in 1986 reported that meso-Z and Z are
present in 21 species of edible fish, shrimp, and sea turtles
[19]. The presence of meso-Z in the serum of unsupple-
mented individuals has never been unambiguously
demonstrated, although efforts to extract and quantify meso-
Z in human blood have demonstrated that, if it is present,
the concentrations of this carotenoid are low [115]. Inter-
estingly, and in spite of its absence or low concentration in a
normal diet, meso-Z accounts for about one-third of the total
MP at the macula, consistent with the finding that retinal
meso-Z is produced primarily by isomerisation of retinal L at
the macula [20, 21].
7 Types of evidence
There is the notable challenge of fitting carotenoid research
into the, sometimes rigid, paradigm of evidence-based
medicine. Harbour and Miller [116] summarised the widely
accepted hierarchy of study types adopted by the Agency for
Health Care Policy and Research:
(i) Systematic reviews and meta-analyses of randomised
control trials (RCTs)
(ii) RCTs
(iii) Non-randomised intervention studies
(iv) Observational studies
(v) Non-experimental studies
(vi) Expert opinion
A systematic review is a thorough, comprehensive and
explicit means by which to identify, critically appraise and
evaluate medical literature related to a specific research
question. A meta-analysis is a statistical approach to
combine and analyse the data derived from a systematic-
review. RCTs are studies in which participants are allocated
at random, rather than by conscious decision of clinician or
patient (which is the case in non-randomised trials), to
receive one of several clinical interventions, one of which
typically acts as a control (placebo). The greater the sample
size, the reduced likelihood of bias. In contrast, an obser-
vational study is one in which conclusions are drawn by
observation alone, examples of which may include case-
control and cohort studies.
Evidence quality is typically graded on the basis of study
design, where systematic reviews or meta-analyses of RCTs
are widely accepted as providing the best evidence (level 1)
on the effects of preventative, as well as other, interventions
in medicine [117]. (see Table 1)
Randomised controlled trials are regarded as the ‘‘gold
standard’’ in clinical research, yet they have certain limita-
tions [118] such as inappropriate outcome measures and/or
biased sample recruitment. Given that studies involving
humans are laden with ethical issues and, in many cases,
may not be feasible, practical or indeed appropriate
[118, 119], many important epidemiologic findings have
been the result of observational studies. The weight accor-
ded to RCTs can, in some instances, result in the exclusion
of evidence arising from other and valid study designs. In
other words, studies with alternative designs should be seen
as complimentary, rather than an alternative, to RCTs.
AMD is a slow, complex disorder and the carotenoids
under review, particularly L and Z, are already commonly
found in the daily diet and are easily available in supplement
form on the open market. This makes the conduct of "gold
standard" randomized clinical trials particularly difficult.
What is important to acknowledge is that all study designs
contribute to an ever-growing body of knowedge in a given
area. This point has been eloquently made by Hennekens
[120]: ‘‘Every research strategy within a discipline, contri-
butes importantly relevant and complimentary information
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Table 1. Levels of evidence for therapy or prevention
Level Type of study
1a Systematic review (homogeneous) of RCTs
1b Individual RCT (with narrow confidence interval)
2a Systematic review of (homogeneous) cohort studies
2b Individual cohort study/low-quality RCT
3a Systematic review of (homogeneous) case-control
studies
3b Individual case-control studies
4 Case series, low-quality cohort or case-control studies
5 Expert opinions without explicit critical appraisal, or
based on physiology, bench research or ‘‘first
principles’’
Material adapted from the recommendations for evidence-based
medicine in Oxford. http://www.cebm.net/index.aspx?o5 1025.
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to a totality of evidence upon which rational clinical decision
making and public policy can be reliably based. In this
context, observational evidence has provided and will
continue to make unique and important contributions to
this totality of evidence upon which to support a judgment
of proof beyond a reasonable doubt in the evaluation of
interventions.’’
While recognising the importance of study design in
public health research, we are encouraged to give adequte
attention to the completeness and transferability of evidence
when interpreting the results of such studies. This has been
eloquently articulated by Rychetnik et al, as follows: ‘‘Care is
needed that the use of evidence hierarchies to compare the
potential for bias between study designs does not translate
into unrealistic or overly expensive demands for level 1 or 2
evidence, particularly if there is a good or adequete level 3
evidence to inform a decision’’ [121].
The reader should also be aware that the capacity and
resources of competing stakeholders (e.g. pharmaceutical
companies, academic institutions, among others) to gener-
ate and disseminate evidence has a profound influence on
the prestige and volume of available and published literature
on a given subject [121].
8 AMD and the macular carotenoids: The
evidence (Table 2)
8.1 Randomised control trials
8.1.1 Proof of principle
In 2001, the Age-related Eye Disease Study (AREDS) was
published, having been conducted by the National Eye
Institute (NEI). This was a double-masked, randomised,
placebo-controlled trial of 4757 subjects over a period of 5
years. In brief, it was shown that supplementation with
vitamins C and E, b-carotene, and zinc in combination
resulted in a 25% risk reduction of progression from inter-
mediate to advanced AMD. Of note, the AREDS did not
supplement with any of the macular carotenoids, primarily
because these compounds were not available in supplement
form at the inception of that study. This important study
did, however, provide level 1 evidence that demonstrates that
supplemental dietary anti-oxidants were beneficial for
patients with AMD.
8.1.2 AMD and the macular carotenoids
There are now many published interventional studies
reporting on AMD and the macular carotenoids (Table 2)
[122–126].
In 2004, the LAST study (Lutein Antioxidant Supple-
mentation Trial) was carried out in an attempt to evaluate
the effect of L, either alone or in combination with addi-
tional carotenoids, anti-oxidants, vitamins and minerals on
the progression of atrophic AMD [125]. This study was a
prospective, 12-month, randomised, double-masked,
placebo-controlled trial, involving 90 subjects with atrophic
AMD. The subjects were assigned to one of three groups:
group 1 received L only (10mg); group 2 received a broad-
spectrum supplementation formula containing L (10mg) as
well as anti-oxidants, vitamins and minerals; group 3
received a placebo. Results showed that the subjects in
Groups 1 and 2 demonstrated an increase in mean MP
optical density as well as an improvement in visual acuity,
contrast sensitivity, glare recovery and visual distortion. This
study, therefore, demonstrated that visual function is
improved in patients with atrophic AMD following supple-
mentation with either L alone or L in combination with anti-
oxidants, vitamins and minerals. However, the LAST study
is open to legitimate criticism on the basis of the small
number of patients recruited into each arm of the investi-
gation, and the short follow-up (ie. only 12 months).
The Carotenoids in Age-related Maculopathy (CARMA)
study was a randomised, double blind, placebo-controlled
clinical trial of L (12mg) and Z (0.6mg) supplementation
with co-anti-oxidants versus placebo in patients with AMD
[127]. This study included 433 subjects, who were recruited
and randomly assigned to the treatment or the placebo arms
of the study. Although the primary outcome measure (best
corrected visual acuity (BCVA) at one year) did not differ
between the placebo and the intervention arms of the study,
it was noted that corrected distance visual acuity was
significantly better in the intervention arm of the study at 36
months follow-up. In addition, an increase in serum L was
associated with significantly improved BCVA and slowing of
progression along the AMD severity scale [126]. It is
important, however, to note there are several limitations in
the CARMA study design, despite it being an RCT. These
limitations include a relatively small sample size, particu-
larly at 36 months (n5 41, 20 in the intervention group and
21 in the placebo group), and the questionable appro-
priateness of its primary outcome measure (BCVA at 12
months), given the chronic nature of AMD.
Moreover, the other studies presented in Table 2,
although RCTs, have several limitations in their respective
study designs, including small sample sizes, stated outcome
measures, and lengths of follow up.
8.1.3 Trials awaiting completion
There are a number of trials underway investigating the
putative protective role of L and Z in individuals with AMD.
The AREDS 2 is an ongoing multi-centre RCT (n5 4000
approximately) designed to evaluate the effect of supple-
mental L and Z (and/or x-3) with respect to the progression
to advanced AMD. Additionally, it seeks to assess whether
modified forms of the original AREDS supplement, with
reduced zinc and/or no b-carotene, work as effectively as the
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original supplement in reducing the risk of progression to
advanced AMD.
The study is expected to be completed in December
2012 (http://clinicaltrials.gov/ct2/show/NCT00345176?term5
AREDS2&rank5 1). The results of AREDS 2 will provide
invaluable and timely data on the potential role of anti-
oxidants, including L and Z, in delaying AMD progres-
sion, and will inform current professional practice with
respect to the role of dietary modification and/or supple-
mentation in patients with AMD. A limitation of the trial,
however, rests on the fact that MP is not being measured.
Therefore, a finding that supplemental L and Z in AREDS 2 is
not beneficial cannot be interpreted to mean that MP
augmentation is not beneficial, as the latter will not have been
demonstrated.
Results from recent studies, as yet unpublished, have
demonstrated visual improvement in response to macular
carotenoid supplementation, and this improvement corre-
lated with the observed increase in MP in eyes afflicted with
AMD [128, 129].
8.2 Future considerations
There have been no published trials investigating the
potential of dietary carotenoids in terms of prevention of
AMD, which would involve recruiting subjects who are not
afflicted with the condition and evaluating the incidence of
AMD with respect to dietary intake of the dietary carote-
noids and with respect to MP optical density. The trial would
be observational in design rather than interventional, as the
study period would need to be not less than 15 years in
duration following completion of recruitment. Of note,
however, a study of such unique design is currently
underway in Ireland. The Irish Longitudinal Study of
Ageing (TILDA) [130], is investigating health, lifestyles and
financial status of circa 8000 randomly selected people aged
50 years and older. A major component of this prospective
cohort study is the investigation into the relationship
between baseline MP levels and the prevalence and inci-
dence of AMD [131]. MP measurements and retinal photo-
graphs are being obtained at three separate study waves:
year 1 (started December 2009, and is now near completion),
year 4 and year 8. This study will investigate, for the first
time, whether baseline MP levels relate to the ultimate risk
of developing AMD.
Furthermore, no trials to date have investigated the
potential of meso-Z with respect to development or
progression of AMD, as it has only recently become avail-
able in supplement form. Of note, meso-Z, which accounts
for one third of total MP [21], and of the three macular
carotenoids, is the most powerful anti-oxidant [107]. Emer-
ging evidence has also shown that the central dip in MP, an
anatomic characteristic associated with the undisputed risk
factors for AMD (ageing and tobacco use) [74], is negated by
a meso-Z dominant supplement [115].
8.3 Observational studies
A large number of studies have investigated the relationship
between dietary intake of the macular carotenoids and AMD
(Table 2) [72, 132–138]. Of these eight published observa-
tional studies, five reported a negative association between
high dietary intake of the carotenoids and AMD. Serum
carotenoid levels and their relationship with AMD risk have
also been assessed [94, 134, 139–144]. Of the eight studies
published, five have demonstrated an inverse association
between serum concentration of the macular carotenoids
and risk for AMD.
8.4 Dietary, serum, and retinal response to
supplementation with the macular carotenoids
There have been many published studies on serum and
retinal response (i.e. MP optical density) to supplementation
with the macular carotenoids (Tables 3 and 4, respectively),
in normal and in AMD subjects.
Of the published studies commenting on serum carote-
noid response following supplementation with macular
carotenoids, a mean(7sd) L concentration increase of
330(7342)% (range: 16 to 1500%) within 19 (range: 3 to 48)
weeks was observed. Similarly, a mean(7sd) increase of
0.16(70.34) (range: 0 to 1.6) in MPOD was observed within
20 (range: 8 to 52) wks. However, it is important to point out
that the magnitude of response is influenced by many
factors, including the type of carotenoid used (i.e. L, Z, meso-
Z, independently or in combination), the concentration of
carotenoid present in the supplement (dose), the duration of
supplementation (time), individual characteristics (e.g.
adiposity), and baseline MP levels.
However, the data suggest that supplementation with all
three macular carotenoids results in the optimal response in
terms of MP augmentation and changes in its spatial profile,
although the data should be interpreted with full apprecia-
tion of the small number of trials involving supplemental
meso-Z. Therefore, and given that the anti-oxidant capacity of
MP is maximised in the presence of all three macular
carotenoids, and where the objective is to augment MP and
to putatively confer protection against AMD, current
evidence suggests that supplementation with all three
macular carotenoids is most likely to limit (photo)-oxidative
retinal injury with a consequential reduction in risk of AMD
development or progression.
Interestingly, a study by Bone and Landrum has shown
that serum levels of L and Z rise and fall rapidly following
commencement and discontinuation of supplementation
with the macular carotenoids, respectively. In contrast, MP
optical density increases more slowly from baseline following
commencement of supplementation with the macular caro-
tenoids, and returns to baseline levels more slowly following
discontinuation of supplementation, reflecting a slow biolo-
gical turnover or these carotenoids at the macula [145].
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8.5 A note on x-3 and AMD
The role of x-3 in AMD has generated considerable debate.
The membranes of the photoreceptor outer segments have
the highest concentration of PUFAs in the mammalian
world [146], and their deficiency is associated with the onset
of AMD [147]. These PUFAs are thought to protect against
oxidative and inflammatory damage [148], processes which
play a key role in the pathogenesis of AMD. On the other
hand, such PUFAs are potentially the ideal substrate for the
propagation of free radical damage associated with AMD
[23]. There is a paucity of evidence for either of these
hypotheses.
Two major systematic reviews have investigated x-3 and
its association with AMD. Hodge et al. appraised the
evidence on the effects of x-3 fatty acids in slowing down
the progression of AMD and/or decreasing the rate of
progression to advanced forms of the disease [149]. Only two
studies were eligible for review, one of which (an RCT)
indicated a beneficial effect of supplemental x-3. However,
confusion arising from the nutrient preparation with which
patients were supplemented rendered it unclear as to
whether x-3 was indeed responsible for any observed
benefit. A systematic review by Chong et al reviewed the
evidence germane to dietary x-3 and fish intake in the
primary prevention of AMD [150], suggesting that the
consumption of fish and foods rich in x-3 may be associated
with a lower risk of AMD. This observational data does not
necessarily indicate that any observed association represents
a protective effect of x-3 fatty acid intake, due to possible
confounding (e.g meso-Z is also found in seafoods, or it may
simply reflect a healthier lifestyle and diet in general
amongst subjects with high consumption of fish).
Of note, AREDS 2 is also investigating the role of
supplemental x-3 in AMD.
9 Concluding remarks
In summary, there is a biologically plausible rationale
whereby MP protects against the development and
progression of AMD. MP properties include its pre-recep-
toral filtration of damaging short-wavelength light and its
ability to quench free radicals, processes which play a key
role in the aetiopathogenesis of AMD. The undisputed risk
factors for AMD (ageing, positive family history of disease
and tobacoo use) are associated with a lack of MP prior to
disease onset. There is level 1 evidence confirming that
supplemental dietary anti-oxidants reduce the risk of vision
loss in AMD, although evidence of this quality for supple-
mentation with the macular carotenoids is still lacking.
Dietary supplementation with the macular carotenoids (L, Z
and/or meso-Z) results in augmentation of MP, and the best
response in terms of augmentation, changes in spatial
profile of the pigment and in terms of global fortification of
the anti-oxidant defenses of the tissue to be protected,
appears to be a supplement containing all three macular
carotenoids. These trials, however, are limited by several
factors, including small numbers of subjects and inadequate
masking, such that definitive conclusions cannot yet be
drawn.
To effectively investigate the putative protective role of
carotenoid supplements in AMD, including a possible role
in prevention of this condition, an RCT of considerable
length (decades) would be required, and securing funding
for such a study would be challenging indeed. As a conse-
quence, it is important that we appraise the totality of
currently available evidence in order to assist eyecare
professionals to make well-informed decisions with respect
to the prevention and/or delay of AMD onset and/or its
progression. In this context, it would appear that supple-
mentation with the macular carotenoids offers the best
means of fortifying the anti-oxidant defenses of the macula,
thus putatively reducing the risk of AMD and/or its
progression.
The authors have declared no conflict of interest.
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